Pacira BioSciences, Inc. and Viatris
Viatris completed its acquisition of Pacira BioSciences for approximately $1.69 billion.
Company-confirmed: reported in the company's own SEC filing
Latest update Nov 17, 2026, 9:44 AM ET
- ✓Announced
- ✓Pending
- ✓Completed
Acquirer
ViatrisVTRS- Deal value
- Not disclosed
- the filing states none
- Offer
- $36.50
- cash
- Premium
- +44.84%
- $36.50 per share in cash against the 2026-10-07 close of $25.20
- Expected close
- Not disclosed
- tender offer
The offer against the share price
Last close before the disclosure and the cash price per share written in the filing.
+44.8% premium over that close
Share prices around the disclosure
Daily closes, each set to 100 on the first day shown. The dashed lines mark the session that first reflects each public event.

